In order to test the hypotheses that mutant huntingtin protein length and wild-type huntingtin dosage have important effects on disease-related transcriptional dysfunction, we compared mRNA changes in seven genetic mouse models of Huntington's disease (HD) and postmortem human HD caudate.
Introduction
Huntington's disease results from a trinucleotide repeat expansion mutation in exon 1 of the huntingtin (HD, IT15) gene. The neurotoxicity of this mutation is conveyed through the expansion of a polyglutamine stretch in the corresponding protein product, huntingtin (htt), which appears to disrupt multiple cellular processes. Among these is the apparent dysregulation of gene expression, which has recently been implicated through transcriptomic profiling and biochemical data on huntingtin protein interactions (reviewed in 1). Interest in this disease mechanism has gained additional momentum by virtue of preclinical trials showing that transcriptionally active drugs ameliorate disease phenotype (2) (3) (4) .
A substantial number of models of HD are available in which to conduct studies aimed at understanding and eventually ameliorating the human disease. Differences between these model systems include the length of htt transprotein, length of polyglutamine repeat, species origin of the mutated htt, host organism species and strain, and levels of htt expression. One may search among such models for answers to a particular etiologic question based on how well the model system recapitulates the corresponding aspect of human disease.
R6 lines of mice were created in the laboratory of Bates and colleagues and were the first of the HD mice to be recorded (5) . R6/2 mice express only the exon 1-encoded portion of the human htt transprotein with a large polyglutamine tract; they have a severe and rapidly declining molecular and behavioral phenotype, with significant motor and mRNA changes by 6 weeks of age (6) (7) (8) . These mice show no significant neuronal loss until later time points, however, ruling out frank degeneration as the source of mRNA changes (9, 10) . R6/1 mice, a sister line to the R6/2, have a similar phenotype which becomes manifest on a slower timescale (5, 11) .
Additional transgenic HD mice expressing short N-terminal htt fragments (such as N171-82Q [12] and HD94 [13] ) also have rapidly declining phenotypes that include changes in striatal gene expression (14, 15) . In contrast, HD mice expressing a longer N-terminal portion of htt with 46 polyglutamine repeats (HD 46 mice [16] ) exhibit no detectable changes in gene expression up to 1 year of age, and a sister line with 100 repeats shows only subtle neurotransmitter receptor changes (16, 17) .
Mouse models designed to recapitulate more precisely the genetic lesion in human HD have been created by inserting CAG repeats into the endogenous mouse Huntington's disease homolog (Hdh) gene (including Hdh4
80Q [18] , Hdh 92Q [19] ; CHL2 150Q [20] ; Hdh 140Q [21] ). Also, transgenic mice have been produced using yeast artificial chromosomes carrying the human huntingtin gene (YAC72 [22] ; YAC128 [23] ). These "full-length" HD models have a normal or near-normal life span but show molecular, cellular, and behavioural phenotypes (19) (20) (21) (23) (24) (25) (26) ; M. Heng and R. Albin, unpublished).
To date, few gene expression changes have been described in murine HD models expressing fulllength mutant htt (17, 21, 25, 27) .
In this report, we elaborate global transcriptomic comparisons between HD mice of all categories and human HD. The present studies focus on gene expression in the striatum, the HD brain region demonstrating both the most dramatic neuropathology and the most extensive mRNA changes.
Our data show that substantial components of the molecular HD phenotype can be captured in model systems, and that these profiles can provide a clear transcriptome-level pattern of disease evolution.
Surprisingly, both N-terminal and full-length mutatnt htt proteins demonstrate similar effects on transcription, whereas no detectable effect could be attributed to wild-type htt. Establishing the significant recapitulation of the transcriptomic HD phenotype by model systems also provides an important basis for further investigations of gene-expression-related HD mechanisms and therapeutics.
Results
Striatal mRNA profiles of seven lines of HD mice expressing various forms of mutant htt (Table 1) and various gene dosages of wild-type htt were compared to each other and to a human HD caudate data set (see 28) . Most of the mice were sampled de novo for these analyses, but cross-comparisons to previous data sets (where n ≥3 arrays were used) were also included. Each HD mouse model was analyzed for differential gene expression compared to age-, gender-and strain-matched wild type counterparts (see Methods). Table 1 provides details of the mouse strains, arrays, and sample numbers employed for each data set.
In order to compare the relative signal magnitudes in each HD mouse data set, we examined the distributions of nominal p values from probeset-wise differential expression tests. Data sets showing a significant signal are expected to have a higher proportion of low p values, whereas the p values in the absence of such a signal should be distributed randomly, giving a flat histogram. As shown in Figure 1 , such a distinct peak of small p values was observed in the 6-week and 12-week R6/2, 22-month CHL2 Q150/Q150 , and 18-month Hdh Q92/Q92 data sets. In order to summarize the strength of the differential gene expression signature, we calculated the number of probesets meeting defined statistical criteria in each model (nominal p value < 0.001 or FDR-corrected p value < 0.05, see Table 1 under heading "Single-gene testing"). The numbers of probesets meeting these criteria was considerably higher for some data sets than for others, indicating different levels of detectable differential expression.
Nonetheless, several models have changes in gene expression which can be identified on a single genetesting basis.
In order to determine the extent to which the various HD models recapitulate the transcriptomic changes in human HD caudate, we compared the mouse HD profiles to microarray data from human samples of pathologic Grade 2 or below (28; complementary analysis in Supplementary data Table S1 ). Quantifying the similarity of each model's overlap to the human data should thus provide a relative measure of its ability to reproduce the signature of HD.
Determining concordant gene expression between human HD and its mouse models considered whether the statistically top-ranked mRNAs in each mouse data set were consistent with the differential mRNA expression observed in human HD caudate. First, the top 200 differentially expressed genes in each model were determined (including both increases and decreases) and each mouse gene was mapped to its corresponding human ortholog. Then the direction of each change in expression was taken into account, and same-direction changes were distinguished from changes with opposite signs ( Figure 2 ). As a third step, a statistical cutoff for the human comparison was implemented in order to restrict the overlap to changes identified as statistically significant in human.
Thus, a concordant change was defined as one showing the same-signed change in expression (increased or decreased in both mouse and human) meeting a false-discovery-rate cutoff of p< 0.05 in the human analysis. For each data set, we then summarized its interaction with human HD data set using a concordance coefficient (c) which tallied concordant minus discordant regulations (as described in Methods; data presented in Table 1 , heading "Comparison to human HD", column "Concordance coefficient"). In order to estimate significance of the relationships between the model and human data sets, we compared the actual concordance coefficients to coefficients obtained from analyses where the human sample labels were randomly assigned ( The qualitative assessment of which models showed bona fide HD signal was similarly assigned using both of these approaches ( Figure 2 ). Providing a relative measure of similarity to human HD, the concordance coefficients and corresponding ranks of all model data sets are presented in Table 1 . In order to visualize the correlation of fold-change and to consider the specific direction of change (increased versus decreased), complementary scatterplots illustrating these features of the data are also presented in Figure 3 . For mouse models with a significant similarity to human HD, there was generally higher concordance between mouse and human data where expression of particular mRNAs was decreased.
Mouse models showing robust HD signal comprised both N-terminal fragment and full-length models.
In order to address particular aspects of HD pathogenesis that might be differentially represented across models and time points, we compared the collected data sets to one another. Based on the different protein contexts of the mutant polyglutamine stretch in the knock-in and N-terminal fragment models, we hypothesized that the two classes of models might show different patterns of gene expression changes. One could postulate, for example, that animals expressing full-length mutant htt might display changes related to both mutant full-length and N-terminal fragment effects and so an additional set of gene expression changes would be evident in these animals. We thus attempted to identify specific gene expression changes that would distinguish between the two types of models, and thereby delineate unique effects of full-length mutant htt.
As preliminary results indicated that array type might have a significant effect on data set discrimination, we increased the homogeneity of comparisons by restricting analyses to data sets collected on arrays with identical probes (MOE 430). Cluster analysis using top knock-in, truncated transgenic, or human HD gene expression changes, or most variable genes across all HD mouse models typically discriminated between data sets with significant HD signal and those without, but provided no discrimination between N-terminal and full-length HD models ( Figure 4 ). On the other hand, the emergent pattern was that models sampled during later stages of disease (22-month CHL2 Q150/Q150 and 12-week R6/2) consistently clustered together. The strong similarity of late stage models is also demonstrated by their correlation coefficients of differential expression (fold-change, Figure 4 , bottom panels), where data from late stage models are more highly correlated with each other than with models of the same respective type (N-terminal or full-length).
When considered together, the numbers and directions of mRNA changes across mouse model and human HD data sets showed interesting relationships (Table 1) . Overall, the earliest stage models exhibited fewer changes, and these were predominantly decreases in expression. As the model phenotype became more severe (as over time with R6/2 or CHL2 Q150/Q150
), the total number of expression changes increased, and the ratio of increased to decreased changes became approximately 1:1. As considered in the previous section, the pattern of molecular changes in the late stage mice is closest to that seen in human postmortem HD tissue. Therefore, it is exciting to consider that the potential continuum of mRNA pathology may be accurately represented by the mice as well, with the early stage mice providing information not readily observable in human HD brain, due to the limited collectibility of human tissues representing the very earliest pathological events.
In order to explore whether there might be identifiable biological explanations for the differences between the late stage and early stage mice, we subjected differential expression lists to cellular and molecular pathways analyses. In order to focus on changes relevant to human HD, we considered only concordant changes in mice whose orthologs were significantly dysregulated in human. Unfortunately, however, gene ontology analyses were unable to detect significantly over-or under-represented pathways in these gene sets and thus no specific differences were revealed.
In order to identify robust molecular indicators that might provide important information about early disease mechanisms, we defined the most consistent gene expression changes across multiple early- Tables S2 and S3 .) The concordant early changes include both expected (DRD2, ADORA2A, CNR1, PENK) and novel mRNAs (RASGRP2, MYT1L, CA12) relative to previous reports, with a large fraction nonetheless being involved in striatal signaling (11, 14, 28) . It is anticipated that use of these robust disease indicators may help to focus transcription-related hypotheses of HD pathogenesis.
Discussion
In this report, we compare the full transcriptomic profile of a human neurological disease with those of genetic murine models of the same disease created in different laboratories. The benefit of this strategy is that it yields an unbiased analysis of the extent to which the mouse model accurately represents the disease it attempts to recapitulate. One noteworthy limitation of this method is that potentially important features of disease beyond mRNA level changes escape detection. Another limitation to be considered is that our data represent only a small number of animals from each line and time point.
Nonetheless, valuable conclusions can be drawn from animals showing significant HD signal, particularly where concordance between multiple models is observed.
Although statistical treatment of microarray expression measures has largely been refined to a point of consensus, strategies for global comparisons between large expression data sets are less well established. Although several methods for testing gene set enrichment have been proposed to define and quantify similarity between transcriptomic information (see review by Khatri and Draghici [29] ;
and also [30, 31] ), one often-discounted element is the sign of differential expression (increased versus decreased). In the context of many problems, such as the one considered here, it is of high biological relevance that the change in expression be concordant between the two systems considered (32); here the modeling would not be considered accurate if, for example, genes underexpressed in human disease were overexpressed in the mouse. We implemented a simple strategy of assessing transcriptomic concordance between mouse and human based on both the rank and sign of the change in each dataset. This measure takes into account the strength of disease signal (i.e. the number of accurately reproduced changes) as well as penalizing "incorrect" regulations. Our proposed measure has a clear biological interpretation and is amenable to statistical testing by appropriate permutation of the data.
The major finding of this study is that several available genetic mouse models of HD faithfully reproduce the transcriptomic changes of the human HD caudate. This is an exciting discovery because it suggests that the process by which these changes arise in the models may also be similar, and therefore the study of these models may translate well to understanding human HD. In addition to being relevant for new target identification, this indicates that the available models may be valid for testing current therapeutic strategies directed at the same pathway(s).
Results of the present study can inform the choice of models to study changes in gene expression and the timeline in which such changes can be expected in various model systems. We cannot be certain about the extent to which the present transcriptomic analyses can be extrapolated to other models, but previous evidence shows that some lines not included here, such as the N171-82Q and HD94, do exhibit similar mRNA changes (14, 15) . Also, a global view of the present data suggests that all mutant htt-expressing mice would show relevant mRNA changes if the rodent lifespan allowed sufficient disease progression.
There are nonetheless some noteworthy differences between the molecular and cellular aspects of the HD models employed here and the corresponding characteristics of the adult-onset human disorder.
The first is that all models demonstrating gene expression changes possess CAG repeat lengths The similarity between the transgenic mouse models and human HD was much stronger for the genes that are downregulated with disease ( Figure 3 ). This finding is consistent with the identification of a set of polyglutamine dysregulated genes subject to an inhibitory effect of mutant htt on the transcriptional machinery (see below). On the other hand, the increases in gene expression observed in models at late stages also show a statistically significant relationship to HD, and therefore should not be discounted. One potential confounding effect in the late-stage mice is that the loss of striatal neurons and relative increase in glial number may account for some of the apparent changes in expression, and we did not address this point in the present study. Whether particular changes in gene expression occur at an mRNA/neuron level will therefore require additional analyses with complementary methods such as in situ hybridization histochemistry or neuronal microdissection (28, 33) . Cell loss in early stage HD mice is absent or minimal, and thus would not be anticipated to have an impact on the array results.
We were surprised not to be able to identify differences between models expressing an N-terminal fragment and those expressing full-length htt proteins. The fact that both have similar effects on gene expression suggests that these effects are caused by the polyglutamine-bearing region of the protein.
On the other hand, the more protracted timeline of this effect in the full-length models is consistent with the hypothesis that transcriptional dysregulation is dependent on the nuclear accumulation of a proteolytically derived N-terminal huntingtin fragment (34) , supporting that the inhibition of this step may be a promising therapeutic strategy.
It is also interesting to consider that the transcriptomic profiles of the mice do not show a discernable effect of the varying copy numbers of genes encoding wild-type htt (Table 1) . For example, the CHL2 Q150/Q150 and R6 mice show similar profiles, despite the fact that the CHL2 Q150/Q150 expresses no wild-type htt at all whereas the R6/2 has two intact copies of the Hdh gene. Taken at face value, this would be inconsistent with a loss-of-htt-function hypothesis (35) , although sequestration of wild-type htt through co-aggregation or some other "dominant-negative" action of mutant htt remain plausible explanations.
Although signaling and metabolic perturbations remain plausible mechanisms for transcriptomic changes in HD (36, 37) , there is considerable support for the hypothesis that mutant htt has a more direct effect on gene expression. The strongest evidence for a link between RNA biogenesis and HD pathogenesis is the observation of aberrant interactions between mutant htt and transcriptional regulatory proteins. These reported interactors include Sp1 (38) , CBP (39), NCoR (40), CtBP (41), CA150 (42) , and REST/NRSF (37) . In most cases, these interactions have been shown to change the factors' abilities to control gene expression in a polyglutamine-length dependent manner.
Polyglutamine-length-dependent inhibition of histone acetylation has also been observed, and reversal of histone acetylation deficits by administration of histone deacetylase inhibitors improves the abnormal phenotype in yeast, Drosophila, cell and mouse models of polyglutamine disease (2, 3, 43, 44) . In parallel, hypermethylation of histones has also been observed, and this can be ameliorated with anthracycline antibiotics in HD mice (45, 46) .
While much is known about transcriptomic dysregulation in HD models, the extent to which this information would be relevant to human disease has not previously been established. The present findings support that HD mice are indeed a valid substrate for studying mechanisms underlying gene expression changes in HD. Further, the reference signature provided by early-stage HD mice may be informative in prioritizing the future study of transcription-related mechanisms of HD pathogenesis.
Materials and Methods

Human and mouse samples and differential gene expression analysis
Human samples, microarray processing and quality control as well as statistical analysis were performed essentially as described in Hodges et al (28 
Comparison of differential gene expression in HD models versus HD patients
Orthologous probesets on mouse and human microarrays were matched using the Bioconductor package annotationTools and HomoloGene, as of August 2006 (52).
Data from each the HD mouse models was compared to the human HD signature as follows: we selected the top N non-redundant probesets (i.e. representing N different genes) showing most significant differential expression between mutant and wild-type animals (i.e. the N non-redundant probesets with highest absolute mod t-statistic) and having one or more orthologous probesets in human data. Note that in case of multiple orthologous probesets (i.e. annotated to a single gene), we retained the orthologous probeset detecting the most significant expression change and excluded the others. Differential mRNA expression reported by pairs of (orthologous) probesets detecting a change in the same direction in mouse and human (i.e. up-or downregulation in both mouse and human) was called concordant; opposite direction changes detected by a pair of orthologous probesets in mouse and human was called discordant (i.e. upregulation in mouse and downregulation in human, or the reverse).
We identified the ranks of orthologous probesets in the list of all human probesets ordered by decreasing evidence of differential expression (i.e. increasing p-value or decreasing absolute value of the mod t statistic) and displayed them in two separate histograms: one for concordant probesets and one for discordant probesets. Strong over-representation of changes in low ranks indicated association between top differentially expressed genes in HD mice and HD patients.
We summarized the association between gene expression changes in mouse models and human by calculating a concordance coefficient. Concordant regulation was defined as a pair of orthologous probesets reporting same-direction differential expression between disease and control (i.e. both up-or both downregulated) where the human probeset showed a significant expression change (FDR<0.05).
Similarly, discordant regulation was defined as two probesets reporting opposite-sign regulations where the human probeset showed a significant expression change (FDR<0.05). Let c the concordance that none of the human orthologs shows significant differential gene expression).
We tested the strength of association between the mouse disease signature (i.e. the N selected differentially expressed mouse genes) and human HD signature, as measured by the concordance coefficient, in two different ways. First, we tested whether the association of the model signature with the human HD signature was significantly stronger than with an arbitrary (non-HD) human signature.
For this purpose, we generated random human signatures by permuting the original gene expression measures Yij: for each probeset i in the human data, we obtained a permuted set of expression values Yij* (with i=1,..,I, I the total number of probesets and j=1,…,J, J the total number of patients) and obtained an estimate of Mi* the log2 fold change between groups for the permuted values by least squares fitting of the statistical model as for the original data (see 'Human and mouse samples and differential gene expression analysis'). The permutation was the same for all I probesets, such that the correlation between different probeset values was left unchanged. We repeated the permutation step and obtained 10'000 estimates of Mi*. This procedure can be used to estimate the distribution of Mi* and test whether mean expression was equal in HD and control patients (i.e. to assess significance of the original Mi, see [53, 54] ). For each permutation, we thus recalculated the (permuted) concordance coefficient c* based on the log fold change for the N selected mouse regulations and the (permuted) log fold change estimates Mi* for the corresponding N orthologous probesets. Thus, c* provided an estimate of the association strength of the HD model signature with a random human signature and the permutation distribution was used to test for an excess of concordance. Specifically, we reject the null hypothesis if #{c*>=c}/10000 < 0.05, and concluded accordingly that the concordance coefficient observed between the HD model and the human HD signature was significantly larger than between the HD model and an arbitrary human signature ( Table 1 , column "p value rand. labels").
Second, we tested if the association of each model signature with the human HD signature was significantly stronger than the association of a corresponding random mouse signature with the human HD signature (Table 1 , column "p value rand. genes"). For each model, we thus generated random mouse signatures by drawing (without replacement) groups of N non-redundant mouse probesets (i.e. N probesets annotated with N different genes) with a least one orthologous probeset in humans. In the case of multiple orthologous probesets, we included the probesets showing the most significant differential expression. For each model, we then obtained the concordance coefficient c* for each of 1'000 random mouse signatures and used this permutation distribution to carry out the test (see [55] for a discussion of these two sampling schemes). Small changes in N (100-1000) did not qualitatively alter the results obtained; data presented in Table 1 , Figure 2 , and Figure 3 is for N=200.
Comparison of gene expression changes in different HD models
To investigate whether subsets of the HD models shared similar patterns of gene expression changes, and, in particular, to ask whether they might recapitulate human HD in different ways, we performed hierarchical clustering. To reduce technical heterogeneity, we limited this analysis to data sets (17) . All other data, this study. Early stage gene expression changes present in multiple models. All genes meeting criteria of mean rank ≤ 1000 for mouse, rank ≤ 5000 in human, and concordant sign of change across all five disease conditions are shown. Number in each column represents log 2 fold-change of differential expression in each HD group.
Tables and Figures
Figure 1:
Nominal p value distributions for differential expression. Model and data set descriptions and differential expression summaries are provided in Table 1 . (Table 1 ).
Figure 3:
Scatterplots of differential expression in model versus human HD. These plots provide additional detail about the concordant and discordant changes shown in Figure 2 and pictorially represent the bases of the concordance coefficients for each model (data in Table 1 Figure 4B
